Clicky

INmune Bio Inc.(INMB)

Description: INmune Bio, Inc. is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors.


Keywords: Biotechnology Cancer Disease Solid Tumors Immune System Immunotherapy Cancer Treatment Hematologic Malignancies Precision Medicine Checkpoint Inhibitor Tumors Of The Hematopoietic And Lymphoid Tissues Residual Disease

Home Page: www.inmunebio.com

INMB Technical Analysis

980 North Federal Highway
Boca Raton, FL 33432
United States
Phone: 858 964 3720


Officers

Name Title
Dr. Raymond Joseph Tesi M.D. Co-Founder, Pres, CEO, Chief Medical Officer & Chairman
Mr. David J. Moss M.B.A. CFO, Treasurer & Sec.
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. Chief Scientific Officer & Chief Manufacturing Officer
Mr. Joshua S. Schoonover Esq. Assoc. Gen. Counsel
Dr. Christopher J. Barnum Head of Neuroscience

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.155
Price-to-Sales TTM: 306.3056
IPO Date: 2019-02-04
Fiscal Year End: December
Full Time Employees: 10
Back to stocks